MY207132A - Anti-tau antibody and use thereof - Google Patents
Anti-tau antibody and use thereofInfo
- Publication number
- MY207132A MY207132A MYPI2022000234A MYPI2022000234A MY207132A MY 207132 A MY207132 A MY 207132A MY PI2022000234 A MYPI2022000234 A MY PI2022000234A MY PI2022000234 A MYPI2022000234 A MY PI2022000234A MY 207132 A MY207132 A MY 207132A
- Authority
- MY
- Malaysia
- Prior art keywords
- tau
- tau antibody
- present
- antibody according
- animal model
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190085233 | 2019-07-15 | ||
| PCT/KR2020/009207 WO2021010712A1 (ko) | 2019-07-15 | 2020-07-13 | 항-타우 항체 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207132A true MY207132A (en) | 2025-01-31 |
Family
ID=74088428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2022000234A MY207132A (en) | 2019-07-15 | 2020-07-13 | Anti-tau antibody and use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220204601A1 (enExample) |
| EP (1) | EP4001305B1 (enExample) |
| JP (1) | JP7595061B2 (enExample) |
| KR (1) | KR102196840B1 (enExample) |
| CN (1) | CN114430744B (enExample) |
| AU (1) | AU2020313751A1 (enExample) |
| BR (1) | BR112022000719A2 (enExample) |
| CA (1) | CA3143811A1 (enExample) |
| CL (1) | CL2022000087A1 (enExample) |
| GB (1) | GB2600599B (enExample) |
| IL (1) | IL289813A (enExample) |
| MX (1) | MX2022000603A (enExample) |
| MY (1) | MY207132A (enExample) |
| PH (1) | PH12022550106A1 (enExample) |
| WO (1) | WO2021010712A1 (enExample) |
| ZA (1) | ZA202200724B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| TWI859197B (zh) | 2019-03-03 | 2024-10-21 | 愛爾蘭商普羅帝納生物科學公司 | 識別ｔａｕ之抗體 |
| WO2023039456A1 (en) * | 2021-09-09 | 2023-03-16 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies targeting acetylated tau and methods of use thereof |
| EP4405680A1 (en) | 2021-09-20 | 2024-07-31 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| KR20250010000A (ko) * | 2022-05-27 | 2025-01-20 | 주식회사 진큐어 | 신규 펩타이드 및 그의 용도 |
| CN115724967A (zh) * | 2022-09-21 | 2023-03-03 | 天津鸿宇泰生物科技有限公司 | 一种识别Tau蛋白N端区域的单克隆抗体及其应用 |
| JP2025540336A (ja) * | 2022-12-08 | 2025-12-11 | アデル，インク | 抗タウ抗体及びペプチドを含む融合体とその用途 |
| WO2024133723A1 (en) | 2022-12-22 | 2024-06-27 | Institut National de la Santé et de la Recherche Médicale | Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy |
| CN116716352A (zh) * | 2023-05-16 | 2023-09-08 | 深圳湾实验室 | Tau蛋白聚集的细胞模型、其构建方法及应用 |
| CN116693682B (zh) * | 2023-06-02 | 2024-04-19 | 涌源合生科技(深圳)有限公司 | 抗Tau蛋白抗体及其制备方法和用途 |
| CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130251731A1 (en) | 2012-03-22 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies |
| CA2869438C (en) * | 2012-04-05 | 2021-08-17 | Ac Immune S.A. | Humanized tau antibody |
| EP2870176A4 (en) | 2012-07-03 | 2016-09-28 | Univ Washington | ANTIBODIES DIRECTED AGAINST TAU |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| AR103713A1 (es) * | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| WO2018106889A1 (en) * | 2016-12-09 | 2018-06-14 | Cogwellin L.L.C. | Diagnosis of alzheimer's disease |
| WO2018117647A1 (ko) * | 2016-12-21 | 2018-06-28 | 주식회사 아델 | 변이된 타우 단백질 단편 및 이의 용도 |
-
2020
- 2020-07-13 BR BR112022000719A patent/BR112022000719A2/pt unknown
- 2020-07-13 WO PCT/KR2020/009207 patent/WO2021010712A1/ko not_active Ceased
- 2020-07-13 GB GB2201160.5A patent/GB2600599B/en active Active
- 2020-07-13 JP JP2022503414A patent/JP7595061B2/ja active Active
- 2020-07-13 CA CA3143811A patent/CA3143811A1/en active Pending
- 2020-07-13 MY MYPI2022000234A patent/MY207132A/en unknown
- 2020-07-13 EP EP20841174.4A patent/EP4001305B1/en active Active
- 2020-07-13 AU AU2020313751A patent/AU2020313751A1/en active Pending
- 2020-07-13 MX MX2022000603A patent/MX2022000603A/es unknown
- 2020-07-13 KR KR1020200086341A patent/KR102196840B1/ko active Active
- 2020-07-13 CN CN202080063893.8A patent/CN114430744B/zh active Active
- 2020-07-13 PH PH1/2022/550106A patent/PH12022550106A1/en unknown
-
2022
- 2022-01-12 US US17/574,227 patent/US20220204601A1/en active Pending
- 2022-01-12 CL CL2022000087A patent/CL2022000087A1/es unknown
- 2022-01-12 IL IL289813A patent/IL289813A/en unknown
- 2022-01-14 ZA ZA2022/00724A patent/ZA202200724B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL289813A (en) | 2022-03-01 |
| CN114430744A (zh) | 2022-05-03 |
| EP4001305A1 (en) | 2022-05-25 |
| GB202201160D0 (en) | 2022-03-16 |
| GB2600599B (en) | 2025-05-21 |
| WO2021010712A1 (ko) | 2021-01-21 |
| CA3143811A1 (en) | 2021-01-21 |
| JP2022541539A (ja) | 2022-09-26 |
| TW202116801A (zh) | 2021-05-01 |
| CN114430744B (zh) | 2024-06-21 |
| AU2020313751A1 (en) | 2022-02-10 |
| US20220204601A1 (en) | 2022-06-30 |
| KR102196840B1 (ko) | 2020-12-30 |
| BR112022000719A2 (pt) | 2022-03-29 |
| EP4001305B1 (en) | 2026-07-01 |
| EP4001305A9 (en) | 2023-05-24 |
| ZA202200724B (en) | 2026-04-29 |
| JP7595061B2 (ja) | 2024-12-05 |
| GB2600599A8 (en) | 2024-12-25 |
| PH12022550106A1 (en) | 2022-11-21 |
| EP4001305A4 (en) | 2022-10-12 |
| CL2022000087A1 (es) | 2023-03-10 |
| GB2600599A (en) | 2022-05-04 |
| MX2022000603A (es) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2600599A8 (en) | Anti-tau antibody and use of same | |
| MX2021014345A (es) | Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas. | |
| EA200701828A1 (ru) | Композиции для лечения ретинол-ассоциированных заболеваний | |
| RU2018122823A (ru) | Мутанты белка f rsv | |
| FI3171891T3 (fi) | Menetelmä | |
| WO2017197253A3 (en) | Peptides and methods for treating neurodegenerative disorders | |
| EP2730659A3 (en) | Treatment and Prophylaxis of Amyloidosis | |
| EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| AU2016210835A8 (en) | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders | |
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| WO2022167816A3 (en) | Antibodies | |
| EP2301959A3 (en) | Motif-grafted hybrid polypeptides and uses thereof | |
| EA201592272A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ | |
| WO2020086406A3 (en) | Anti-npr1 antibodies and uses thereof | |
| WO2022020652A3 (en) | Stapled peptides and methods thereof | |
| BR112014024751A2 (pt) | antígenos de clostridium difficile | |
| WO2019014260A3 (en) | BLOOD COMPONENT POTENTIATION OF ANTIBACTERIAL ACTIVITY OF THE LYTIC PROTEIN AND METHODS AND USES THEREOF | |
| MX2018004109A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| MY201355A (en) | "compositions comprising amino acids for use in the prevention and treatment of liver diseases" | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| WO2018208011A3 (ko) | β-아밀로이드 단백질의 응집을 억제하는 생체친화적 펩타이드 | |
| PH12012501743A1 (en) | Antigen binding proteins specific for serum amyloid p component | |
| WO2006087550A3 (en) | Amyloid-binding peptides, analogues and uses thereof |